HCV Drugs

Medical Advocates
Pegylated Interferon Alfa-2a (Pegasys)

Hepatic Disease Main Page

New and Noteworthy
FDA Alerts
Hepatitis B
Hepatitis C
HIV
HIV/HBV
HIV/HCV

HCV Drugs Main New/Newsworthy Home Page

Last Update: September 10, 2011
Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader

New and Noteworthy

September 2011

Effect of an induction period of pegylated interferon-α2a and ribavirin on early virological response i
n HIV-HCV-coinfected patients: results from the CORAL-2 study.
Tural C, Solà R, Alvarez NP, et al Antivir Ther. 2011;16(6):833-841

FDA Alerts

Label Change: Adverse Events
US FDA
May 2005

HIV

Journal Papers, Abstracts, and Commentaries

Safety, Tolerability, and Mechanisms of Antiretroviral Activity of Pegylated Interferon
Alfa-2a in HIV-1-Monoinfected Participants: A Phase II Clinical Trial.
Asmuth DM, Murphy RL, Rosenkranz SL, et al
J Infect Dis. 2010 Apr 26
Abstract

HCV Drugs Main New/Newsworthy Home Page

Pegylated Interferon alfa-2a
Hepatic Disease Main Page